Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View Article